Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2006)

21 slides from Pharmacyclics's technical presentation, Jun 6, 2006

  1. Slide 1: Motexafin Gadolinium Combined with Prompt Whole Brain Radiation Therapy: Phase 3 Trial Results

    Motexafin Gadolinium (MGd) Combined with Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer Patients with Brain Metastases: Results of a Phase 3 Trial M. P. Mehta, R. Gervais, P. Chabot, W. R. Shapiro, R. A. Patchell, M. J. Glantz, L. Recht, S.

  2. Slide 2: Prior Phase 3 trial: consistent benefit in lung cancer

    mS WE Time Since Rando Consistent benefit seen in lung cancer (N=251/401 ) — Time to neurologic progression by blinded Events Review Committee (p=0.048) — Time to neurologic progression by investigator (p=0.025) — Time to neurocognitive progression (p=0.062) — Reduction in death from brain metastase

  3. Slide 3: Study Design

    Study Design + Stratification: — KPS (70-80 vs. 90-100) 5 mg/kg/d x 10 d — Age (< 65 yrs vs. >65 yrs) - Center um,

  4. Slide 4: Major Eligibility Criteria

    Major Eligibility Criteria * Inclusion — Brain metastases from non-small cell lung cancer —KPS score of > 70 * Exclusion — Liver metastases — Extracranial mets in 2 or more organs — Prior WBRT — Prior radiosurgery for brain mets » Unless 1 treatment to 3 lesions — Prior total resection of single bra

  5. Slide 5: Endpoints

    Endpoints + Primary — Time to neurologic progression or death with evidence of neurologic progression as determined by a blinded, centralized Events Review Committee (ERC) + Secondary — Time to neurologic progression, as determined by the investigator — Time to neurocognitive progression — Survival

  6. Slide 6: Assessments

    Assessments Visit schedule: monthly x 8, then q 2 months Standardized Neurologic Examination Standardized neurocognitive testing using a battery of validated tests assessing — Memory — Verbal Fluency — Executive function Neurologic symptoms

  7. Slide 7: Time to Neurologic Progression Endpoint

    Time to Neurologic Progression Endpoint + ERC evaluated blinded data centrally + Endpoint measured major decline in neurologic function, based on prespecified events, e.g., — Change in level of consciousness (stupor/coma) — Aphasia/Dysphasia/Dysarthria —Hemiparesis — New visual field defect — Ataxia

  8. Slide 8: Statistics

    Statistics + Sample size (N=550) — 2-sided a: 0.001 — Power: 0.8 — Hazard Ratio: 0.65 — Event rate: 50% + Follow-up: 6 months after last randomization

  9. Slide 9: Accrual by Country Patients Randomized

    Accrual by Country 554 Patients Randomized Dec 2003- Mar 2005 Austria Belgium - NL 1% 2% Australia 3%

  10. Slide 10: Prognostic Factors

    Prognostic Factors By Treatment Arm Median Age Median KPS Men (%) ‘Adenocarcinoma (% ) ‘Squamous Cel (%) Large Cel (%) BronchoaWeolar Newly Diagnosed (% ) mMGd Multiple Brain Metastases (% ) mControl Extracranial Metastases (4 ) RPACIass 1 (%) RPACHss2(%) Neurologic Symptoms (% ) Brain Met Dxto Rand

  11. Slide 11: Treatment Compliance

    Treatment Compliance Intended MGd doses Administered Intended WBRT Fractions Given 0 10 20 30 49 50 60 70 80 90 100 Percent Motexafin Gadolinium administration did not interfere with the ability to deliver WBRT

  12. Slide 12: Time to Neurologic Progression

    Time to Neurologic Progression Intent-to-Treat Population (N=554) 10 09 Median Time to Neurologic Progression 8 08 MGd: 15.37 months (95% Cl: 10.70, 24.20) ov WBRT: 10.03 months (95% CI: 7.43, 13.50) i os Bos 504 E03 3 Med = 02) p=0.12 (stratified log rank) 01) HR=0.78 WBRT oo DOMIM2M3M4MSMGM7M8 M10

  13. Slide 13: Proportion progression free

    Proportion progression free Time from Brain Metastasis Diagnosis to Neurologic Progression Intent-to-Treat Population (N=554) Median Time to Neurologic Progression 1.0 o9 MGd: 15.53 months (95% Cl: 11.03, 26.03) os WBRT: 10.23 months (95% CI: 8.70, 15.43) o7 os 0s 04 03 02) p=0.05 (stratified log ra

  14. Slide 14: Time Interval from Brain Metastasis Diagnosis to Randomization Predicts Treatment Effect

    Time Interval from Brain Metastasis Diagnosis to Randomization Predicts Treatment Effect Time Interval from Day Median | Median | Hazard | P-Value? of Brain Met Diagnosis TNP. TNP. Ratio? upito WBRT MGd 2 Weeks 274 10.0 24.2 0.61 0.031 4 Weeks 435 88 24.2 0.69 0.038 6 Weeks 489 88 15.4 0.75 0.087 8

  15. Slide 15: Distribution of Patients by Time from Brain Metastasis Diagnosis to Randomization

    Distribution of Patients by Time from Brain Metastasis Diagnosis to Randomization N(%) 0-2 weeks 2-4 weeks >4 weeks Overall 274 (49.5%) 161 (29.1%) 119 (21.5%) North America 208 (59.8%) 106 (30.5%) 34 ( 9.8%) Rest of World 66 (32.0%) 55 (26.7%) 85 (41.3%) France 26 (22.2%) 25 (21.4%) 66 (56.4%)

  16. Slide 16: Patients Receiving Chemotherapy

    Patients Receiving Chemotherapy As Initial Treatment for Brain Metastases Country/Region/Site HS CHanotieraRy N N ‘ North America 348 6 1.7 USA 185 6 3.2 Canada 163 0 0.0 ROW 206 36 17.5 France 117 25 21.4 Site 186 34 13 38.2 Site 211 10 2 20.0

  17. Slide 17: Time to Neurologic Progression: North America

    Time to Neurologic Progression North America (N=348) 1.0 09 08 Median Time to Neurologic Progression MGd: 24.20 months (95% Cl: 11.60, Unk) WBRT: 8.80 months (95% CI: 7.33, 20.20) o7 06 05 04 03 02) p= 04 0.0 004 (stratified log rank) 53 Proportion Progression Free DOMIM2M3M4MSM6M7M8 M10 M12 M14 M16

  18. Slide 18: Salvage Therapy for Brain Metastasis Progression

    Salvage Therapy for Brain Metastasis Progression All Patients. WBRT MGd N=554 N= 275 N=279 N % | N | % Patients Treated with Salvage Brain Radiation oa ee WZ do | ae 65 42 23 Median Time to Salvage Radiation (Days) 208 188 246 Patients Treated with Salvage Brain Surgery dy 2 a2 : us

  19. Slide 19: Most Common Drug-Related Adverse Events

    Most Common Drug-Related Adverse Events (Any Grade) Skin Discoloration Urine Discoloration Nausea Fatigue Hypertension Diarhea Headache Vomiting Blister Scleral Discoloration 0 20 40 60 80 100 Percent of Patients

  20. Slide 20: Most Common Drug-Related Grade Adverse Events

    Most Common Drug-Related Grade 2 3 Adverse Events Hypertension 4.0 Fatigue fm 2.9 ALT Increase fa 2.6 GGT increase fp 2.2 Asthenia fo 1.8 Muscular Weakness [0 1.5 Diarrhea [4,5 LFT abnormality 9 1.5 Nausea fp 1.1 Vomiting p 1.1 Sensory Neuropathy [» 1.1 0 20 40 60 80 100 Percent of Patients

  21. Slide 21: Conclusions

    Conclusions Motexafin gadolinium prolonged time to neurologic progression (N=554): In North America, motexafin gadolinium prolonged time to neurologic progression (N=348): - 8.8 mo to 24.2 mo, p=0.004, HR=0.53 Motexafin gadolinium was well tolerated, and did not compromise ability to deliver radiati

Pharmacyclics — Technical Presentation (June 2006) on 6ix